This Article Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Brauw, L. M. d. Articles by de Bruijn, E. A. Search for Related Content PubMed PubMed Citation Articles by Brauw, L. M. d. Articles by de Bruijn, E. A.

Pharmacological Evaluation of Experimental Isolated Liver Perfusion and Hepatic Artery Infusion with 5-Fluorouracil¹

Department of Surgery [L. M. d. B., A. M., C. J. H. v. d. V.], University Hospital of Leiden, P.O. Box 9600, 2300 RC Leiden, The Netherlands; Department of Analytical Chemistry [U. R. T., C. E.], Center for Bio-Pharmaceutical Sciences, Gorlaeus Laboratories, Einsteinweg 5, P.O. Box 9502, 2300 RA Leiden, The Netherlands; Laboratory of Cancer Research and Clinical Oncology [E. A. d. B.], Antwerp University, Antwerp, Belgium; Department of Medical Statistics [J. H.], Wassenaarseweg 80, 2333 AL Leiden, The Netherlands

The intention of this study was to estimate the pharmacological advantage of a clinically applicable method of isolated liver perfusion (ILP) over hepatic artery infusion (HAI) administering various doses of 5-fluorouracil (FUra). FUra concentrations were measured using high-performance liquid chromatography in liver tissue (pigs and rats), hepatic tumor tissue (rats), and in the systemic circulation (pigs) following ILP and HAI.

Forty-two pigs and 36 rats were subjected to either ILP or HAI with 20, 40 or 80 mg of FUra/kg of body weight. ILP resulted in significantly increased FUra concentrations in the liver as compared with the results with HAI in rats and pigs. Median areas under the concentration-time curve in liver tissue were 122.7 µmol·g^-1·min and 59.9 µmol·g^-1·min (40-mg/kg dose-group) and 236.3 µmol·g^-1·min and 45.1 µmol·g^-1·min (80 mg/kg) for ILP and HAI, respectively in pigs (both P < 0.05). Systemic plasma areas under the curve were significantly lower for ILP as compared with HAI in 40- and 80-mg/kg dose-groups with 2.2 µmol·ml^-1·min and 9.2 µmol·ml^-1·min (40 mg/kg; P < 0.01) and 6.8 µmol·ml^-1·min and 43.2 µmol·ml^-1·min (80 mg/kg; P < 0.01) for ILP- and HAI-treated pigs, respectively. In hepatic tumor tissue a dose-dependent increase of mean FUra concentration was found for ILP-treated rats (P < 0.05). No significant differences were observed in median FUra concentrations in tumor tissue between ILP- and HAI-treated rats (0.66 µmol·g^-1 and 0.63 µmol·g^-1 for ILP- and HAI-treated groups with 80 mg/kg; P > 0.05). The mean FUra concentration tumor/liver ratio was 0.26.

In order to clarify the metabolic fate of high-dose FUra, five rats were subjected to HAI with 150 mg of FUra/kg, and hepatic tumor extracts excised at t = 0 min, t = 5 min, and t = 15 min after infusion were analyzed using ¹⁹F nuclear magnetic resonance. Catabolite -fluoro-ß-alanine appeared rapidly at t = 5 min and t = 15 min in liver tissue. Significant amounts of the presumed active nucleotides were not detected in tumor tissue. We conclude that ILP is a means to improve selectivity of administration of antitumor agents to the liver, as compared with HAI. The pharmacological advantage of ILP over HAI administering equivalent doses of FUra was not demonstrated in tumor tissue, because of a large differential between liver tissue extraction and tumor tissue extraction of FUra, which was influenced by the mode of administration.

¹ Supported by Grant IKW 84-52 from The Netherlands Cancer Foundation.

² To whom requests for reprints should be addressed.

Received 12/18/89. Accepted 1/ 3/91.

This article has been cited by other articles:

				F. Brunstein, A. M. M. Eggermont, G. aan de Wiel-Ambagtsheer, S. T. van Tiel, J. Rens, and T. L. M. ten Hagen Synergistic Antitumor Effects of Histamine Plus Melphalan in Isolated Hepatic Perfusion for Liver Metastases Ann. Surg. Oncol., February 1, 2007; 14(2): 795 - 801. [Abstract] [Full Text] [PDF]

				J. M.H. Hendriks, P. E.Y. Van Schil, G. De Boeck, P. R.M. Lauwers, A. A.T. Van Oosterom, E. A.E. Van Marck, and E. J.M. Eyskens Isolated lung perfusion with melphalan and tumor necrosis factor for metastatic pulmonary adenocarcinoma Ann. Thorac. Surg., November 1, 1998; 66(5): 1719 - 1725. [Abstract] [Full Text] [PDF]